Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Atul V. Butala

Hematology Oncology | Palliative Medicine | Hematology
Mvhs Inc
1676 Sunset Ave, 
Utica, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Embryonal Tumor with Multilayered Rosettes
Mvhs Inc
1676 Sunset Ave, 
Utica, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Atul Butala is a Hematologist Oncology specialist and a Palliative Medicine provider in Utica, New York. Dr. Butala is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Myelodysplastic Syndrome (MDS), Metastatic Pleural Tumor, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration.

His clinical research consists of participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Palliative Medicine
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Wynn Hospital
Rome Memorial Hospital, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MVHS INC
1676 Sunset Ave, Utica, NY 13502

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials
Similar Doctors
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Rahul Seth
Hematology Oncology | Hematology | Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Rahul Seth
Hematology Oncology | Hematology | Oncology

Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In

750 E Adams St, 
Syracuse, NY 
 (44.7 miles away)
315-464-4457
Languages Spoken:
English
See accepted insurances

Rahul Seth is a Hematologist Oncology specialist and a Hematologist in Syracuse, New York. Dr. Seth is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, Large-Cell Immunoblastic Lymphoma, and Familial Pancreatic Cancer.

Sam Benjamin
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Sam Benjamin
Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Sam Benjamin
Oncology

Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In

750 E Adams St, 
Syracuse, NY 
 (44.7 miles away)
315-464-4457
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sam Benjamin is an Oncologist in Syracuse, New York. Dr. Benjamin is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Inflammatory Breast Cancer.

Experienced in Embryonal Tumor with Multilayered Rosettes
Dr. Adriana Lisinschi
Hematology Oncology | Hematology | Oncology
Experienced in Embryonal Tumor with Multilayered Rosettes
Dr. Adriana Lisinschi
Hematology Oncology | Hematology | Oncology

New York Oncology Hematology PC

1700 Riverfront Ctr, 
Amsterdam, NY 
 (54.9 miles away)
518-843-0020
Languages Spoken:
English
See accepted insurances

Adriana Lisinschi is a Hematologist Oncology specialist and a Hematologist in Amsterdam, New York. Dr. Lisinschi is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Butala's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 30 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile